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Idiopathic intracranial hypertension (IIH) is characterized by intracranial pressure >28
cmH2O in the absence of identifiable causes. Aim of this paper is to describe the clinical
phenotype of pediatric IIH and to analyze the applicability of ICHD-3 criteria in comparison
to the ICHD-2. We conducted a retrospective analysis of full clinical data of pediatric
patients diagnosed with IIH between January 2007 and June 2018. Diagnostic evaluation
included neuroimaging (all patients) and ultrasound-based optic nerve sheath diameter
measurement (9 patients). Diagnosis of IIH was verified according to both ICHD-2 and
ICHD-3 criteria for headache attributed to IIH, to verify the degree of concordance.
We identified 41 subjects with suspected IIH; 14 were excluded due a diagnosis of
secondary IH or lack of data. We therefore selected 27 subjects (age 4–15 years, mean
11). All patients presented with headache and bilateral papilloedema. Headache was
daily in 22% cases, with diffuse gravative pain in 41%. In 4%, pain was exacerbated
by cough, stress or tension. The most common presentation symptoms, in addition to
headache, were blurred vision or diplopia (70%), vomiting (33%), and dizziness (15%).
Twenty patients (74%) were obese. In 6 patients (22%) neuroimaging showed empty
sella. Optic nerve sheath distension was detected in 6 out of 9 patients. Regarding
the applicability of the ICHD-2 criteria, 18/27 (71%) patients have criterion A; 24/27
(89%) criterion B; 27/27 (100%) criterion C; 27/27 (100%) criterion D. When the ICHD-3
criteria were used, 27/27 (100%) fitted criterion A; 24/27 (89%) criterion B; 27/27 (100%)
criterion C; and 27/27 (100%) criterion D. Our study suggests that, as compared with
the ICHD-2, the new ICHD-3 criteria for headache attributed to IIH are better satisfied
by pediatric patients with IIH. This is mainly due to the fact that qualitative headache
characteristics are no longer considered in ICHD-3. Although the risk of under-rating the
symptom of headache in IIH should not be disregarded, in pediatric population headache
characteristics are usually less defined than in adults and obtaining a precise description
of them is often very difficult.
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INTRODUCTION
Idiopathic intracranial hypertension (IIH), also known as
pseudotumor cerebri syndrome (PTC), is a rare pediatric
neurological disorder (1). It is characterized by increased
intracranial pressure (ICP) in the absence of any brain
parenchymal lesions, vascular malformations, hydrocephalus,
or central nervous system (CNS) infection (2). The diagnosis
is usually confirmed by high opening pressure (OP) of
cerebrospinal liquid (CSF) (more than 25 cm H2O), provided
there are no secondary causes of intracranial hypertension. In
2013, the opening pressure (OP) for children aged from 1 to 18
years of age was redefined, and the upper limit for a normal OP
is actually 28 cm H2O in the pediatric population (1, 3).
IIH is more frequent in females (females-males ratio 4:1),
especially in the reproductive age, with overweight being a
significant adjunctive risk factor. Indeed, in fertile age overweight
females, the estimated incidence is 12–20 per 100,000 people per
year, vs. a general incidence in the adult population of 0.5–2
per 100,000 (4, 5). The exact prevalence of IIH in the pediatric
population is not yet well established. Recently, studies from
the United Kingdom applying the Friedman criteria revealed an
annual incidence of 0.71 per 100,000 (1, 6).
The pathogenesis of IIH is still largely unknown. ICP is
determined by the balance between production and absorption
of CSF. According to the Monro-Kellie rule, an increase in
ICP might be related to increased CSF, expanded brain tissue,
or increased blood volume (7). Proposed hypotheses include
excess of CSF production, CSF outflow reduction, increase in
cerebral blood volume and/or brain water content, obstruction
to venous system, endocrinological or metabolic causes, chronic
inflammation, and obesity (in pre- and post-pubertal females)
(8–15).
The characteristic signs and symptoms of IIH were initially
described by Dandy and were later organized into the Modified
Dandy Criteria by Smith, combining the lack of other causes
of increased ICP (such as neoplasms and cerebral venous
sinus thrombosis—CVST), with the presence of the following
features: symptoms of increased ICP, papilloedema and raised
opening cerebrospinal fluid (CSF) pressure at lumbar puncture
(LP) (16) (see Table 1). In 2013, revised diagnostic criteria
for IIH have been published by Friedman and coworkers, not
including symptoms of raised ICP (Table 2) (3). According
to these revised criteria, IIH can be classified as “definite”
(increased OP and either papilloedema or abducens nerve
palsy), “probable” (normal CSF pressure in presence of
papilloedema), or “suggestive of” (raised CSF pressure plus
at least three valid neuroimaging markers of raised ICP,
in the absence of papilloedema and abducens nerve palsy)
(3).
Headache is the most common presentation symptom of IIH.
However, the characteristics of the headache in IIH patients
are widely variable and not specific to IIH. Headache is often
referred as unusually severe and can be lateralized and throbbing
or pulsatile. It can be intermittent or persistent, occurring
daily or less frequently, and nausea and vomiting can be
present. Headache can be exacerbated by posture changes,
TABLE 1 | Modified Dandy Criteria (16).
1. Signs and symptoms of increased intracranial pressure (headaches,
nausea, vomiting, transient obscurations of vision, papilledema).
2. No localizing neurologic signs otherwise, with the single exception being
unilateral or bilateral VI nerve paresis.
3. CSF can show increased pressure, but no cytologic, or chemical
abnormalities otherwise.
4. Normal to small symmetric ventricles must be demonstrated (originally
required ventriculography, but now demonstrated by CT).
TABLE 2 | Diagnostic criteria for pseudotumor cerebri syndrome.
1. Required for diagnosis of pseudotumor cerebri syndromea
A. Papilledema
B. Normal neurologic examination except for cranial nerve abnormalities
C. Neuroimaging: Normal brain parenchyma without evidence of
hydrocephalus, mass, or structural lesion and no abnormal meningeal
enhancement on MRI, with and without gadolinium, for typical patients
(female and obese), and MRI, with and without gadolinium, and magnetic
resonance venography for others; if MRI is unavailable or contraindicated,
contrast-enhanced CT may be used
D. Normal CSF composition
E. Elevated lumbar puncture opening pressure [≥250mm CSF in adults
and ≥280mm CSF in children (250mm CSF if the child is not sedated
and not obese)] in a properly performed lumbar puncture
2. Diagnosis of pseudotumor cerebri syndrome without papilledema
In the absence of papilledema, a diagnosis of pseudotumor cerebri
syndrome can be made if B–E from above are satisfied, and in addition the
patient has a unilateral or bilateral abducens nerve palsy
In the absence of papilledema or sixth nerve palsy, a diagnosis of
pseudotumor cerebri syndrome can be suggested but not made if B–E from
above are satisfied, and in addition at least 3 of the following neuroimaging
criteria are satisfied:
i. Empty sella
ii. Flattening of the posterior aspect of the globe
iii. Distention of the perioptic subarachnoid space with or without a
tortuous optic nerve
iv. Transverse venous sinus stenosis
aA diagnosis of pseudotumor cerebri syndrome is definite if the patient fulfills criteria A–
E. The diagnosis is considered probable if criteria A–D are met but the measured CSF
pressure is lower than specified for a definite diagnosis.
and some patients may report relief with non-steroidal anti-
inflammatory drugs and/or rest, although drug refractoriness
is common. Therefore, in most cases, headache characteristics
are similar to migraine and tension-type headache (17). If
retrobulbar pain and pain with eye movement or globe
compression are present, they can be highly suggestive of IIH
(17). Since headache may be the main symptom of changes
in ICP, diagnostic criteria for “Headache attributed to IIH”
have been published by the Headache Classification Committee
of the International Headache Society (IHS) in the second
international classification of migraine disorders in 2004 and
subsequently modified in 2018 in the third classification (18,
19) (Tables 3, 4). Some patients, especially younger children,
might present intracranial hypertension without headache
(20). In the absence of headache, the diagnosis is often
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TABLE 3 | ICHD-2 criteria for headache attributed to IIH (19).
Headache attributed to IIH
(A) Progressive headache with at least one of the following characteristics
and fulfilling criteria C and D:
1. Daily occurrence
2. Diffuse and/or constant (non-pulsating) pain
3. Aggravated by coughing or straining
(B) Intracranial hypertension fulfilling the following criteria:
1. Alert patient with neurological examination that either is normal or
demonstrates any of the following abnormalities:
(a) Papilloedema
(b) Enlarged blind spot
(c) Visual field defect (progressive if untreated)
(d) Sixth nerve palsy
2. Increased CSF pressure (200mm H2O in the non-obese, 250mm H2O in
the obese) measured by lumbar puncture in the recumbent position or by
epidural or intraventricular pressure monitoring
3. Normal CSF chemistry (low CSF protein is acceptable) and cellularity
4. Intracranial diseases (including venous sinus thrombosis) ruled out by
appropriate investigations
5. No metabolic, toxic or hormonal cause of intracranial hypertension
(C) Headache develops in close temporal relation to increased intracranial
pressure
(D) Headache improves after withdrawal of CSF to reduce pressure to
120–170mm H2O and resolves within 72 h of persistent normalization of
intracranial pressure
TABLE 4 | ICHD-3 criteria for headache attributed to IIH (18).
Headache attributed to IIH
(A) New headache, or a significant worsening of a pre-existing headache,
fulfilling criterion C
(B) Both of the following:
1. Idiopathic intracranial hypertension (IIH) has been diagnosed
2. cerebrospinal fluid (CSF) pressure exceeds 250mm CSF (or 280mm
CSF in obese children)
(C) Either or both of the following:
1. Headache has developed or significantly worsened in temporal relation to
IIH, or led to its discovery
2. Headache is accompanied by either or both of following:
a) pulsatile tinnitus
b) papilloedema
(D) Not better accounted for by another ICHD-3 diagnosis
suggested by accidental finding of papilloedema during routine
ophthalmologic evaluations.
OBJECTIVE OF THE STUDY
The aim of this study was to analyze the applicability of the new
ICHD-3 criteria in comparison to the ICHD-2 criteria in a sample
of pediatric patients suffering from headache attributed to IIH.
PATIENTS AND METHODS
We retrospectively analyzed clinical, laboratory, and
neuroimaging data of pediatric patients admitted for headache
and finally diagnosed with IIH in the Headache Center of
Bambino Gesù Children’s Hospital between January 2007 and
June 2018. Patients with incomplete data for whom a complete
verification of diagnosis was not possible were not included
in the present study. Also patients with secondary IH have
been excluded. Diagnostic evaluation included neuroimaging
studies for all patients, and in some cases ultrasound-based
optic nerve sheath diameter (ONSD) measurement. All
patients/parents/caregivers have been contacted by phone to
evaluate whether they suffered from headache before the acute
episode, and to understand if clinical characteristics presented
some differences.
In all patients diagnosis of IIH was verified both according to
ICHD-2 and ICHD-3 criteria for headache attributed to IIH, to
verify the degree of concordance.
RESULTS
We identified a total of 41 subjects diagnosed with IIH.
Four patients have been excluded due to the identification
of possible causes of IH (including cyclosporin therapy and
hypoparathyroidism); 10 patients received a clinical diagnosis
based on the presence of headache, papilloedema, and obesity,
but have been excluded due to lack of data (lumbar puncture
not performed or data not available). We therefore selected
27 subjects (15 F, 12M), ranging between 4 and 15 years of
age (mean age 11 years). All patients presented with headache
and physical examination revealed the presence of bilateral
papilloedema in all of them. Only 3 of them (patients #3, #10,
#19) reported a previous history of headache, but in all of
them pain characteristics were quite different with more severe
symptoms and unsatisfactory response to analgesic treatment.
Despite clinical features were highly suggestive for IIH in all
patients, in 3 of them the opening pressure of CSF was <
25 cmH2O thus not satisfying all criteria for the diagnosis
of IIH. As for headache characteristics, it was daily in 22%
of cases, with diffuse gravative pain in 41% of cases, while
throbbing headache was present in 15% of patients. Moreover,
in 4% of patients, headache was exacerbated by cough, stress or
tension, and in 11% it had a unilateral distribution. The most
common presentation symptoms, in addition to headache, were
blurred vision or diplopia (70%), vomiting (33%), and dizziness
(15%). Twenty patients (74%) were obese (weight centile ≥
90%).
In the majority of patients neuroimaging was normal, while
in 6 patients (22%), MRI or CT showed signs of empty sella
syndrome. Ultrasound-based ONSD measurement was obtained
only in 9 patients, in six of whom an optic nerve sheath distension
could be demonstrated. Clinical characteristics of our sample are
summarized in Table 5.
Regarding the applicability of the ICHD-2 criteria, 18/27
(71%) patients have criterion A; 24/27 (89%) criterion B; 27/27
(100%) criterion C; 27/27 (100%) criterion D. When ICHD-3
criteria were used, 27/27 patients (100%) fitted criterion A; 24/27
(89%) criterion B; 27/27 (100%) criterion C; and 27/27 (100%)
criterion D.
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TABLE 5 | Clinical characteristics of patients.
N Age Headache Dizziness Vomiting Papilloedema Visual disturbances Obesity/BMI Opening pressure Neuroimaging ONSD
1 6y10m y n n y n y/30,2 30 cmH2O Normal np
2 11y y n n y y y/31,1 29.9 cmH2O Normal n
3 11y7m y n n y y y/32 40 cmH2O Normal y
4 12y2m y y y y y y/31,6 71 cmH2O Normal y
5 13y y n n y y y/33,2 36 cmH2O Normal y
6 11y y n n y y y/30,9 53 cmH2O Normal np
7 9y y y n y y Y/33 38 cmH2O Normal np
8 15y y y n y n y/32 40 cmH2O Normal np
9 9y y n y y y y/35,2 40.7 cmH2O Normal n
10 10y y n y y y N/22,3 40 cmH2O Empty sella np
11 12y y n n y y n/19 44 cmH2O Normal np
12 14y8m y n y y y n/16,7 65 cmH2O Normal np
13 11y9m y n n y n y/33,4 55.7 cmH2O Normal np
14 11y2m y n y y y y/32,1 89 cmH2O Normal np
15 13y7m y n y y y Y/30,2 47.5 cmH2O Normal np
16 12y y n n y y y/36,3 54 cmH2O Normal np
17 15y4m y n n y y y/37,2 48 cmH2O Empty sella n
18 7y4m y n n y y y/33,3 45 cmH2O Empty sella np
19 11y11m y n n y n y/57,7 29 cmH2O Normal np
20 12y11m y n n y y n/18,9 35 cmH2O Normal y
21 9y3m y y n y y n/19,8 28 cmH2O Normal np
22 4y8m y n y y n n/19 37 cmH2O Normal y
23 9y1m y n y y n y/34,1 36 cmH2O Normal np
24 11y y n n y n n/21,3 50 cmH2O Empty sella np
25 12y y n n y n y/33,6 21 cmH2O Normal y
26 9y9m y n n y y y/35,3 20 cmH2O Empty sella np
27 10y y n y y y y/39 24 cmH2O Empty sella np
y, yes; n, no; np, not performed; ONSD, optic nerve sheath diameter.
DISCUSSION
To the best of our knowledge, this is the first study comparing the
applicability of the new ICHD-3 criteria to pediatric headache
attributed to IIH. According to the results obtained by our
study, the new ICHD-3 criteria seem to be applicable and
valid for a higher rate of subjects clinically presenting with
symptoms suggestive of IIH. In particular, in our clinical
series, the difference was evident in the criterion A, which
was fulfilled by all patients when applying ICHD3, but only
by 71% when considering the old ICHD2 version. Certainly,
this is due to the disappearance of specificity criteria for
the headache, which now is no longer required to be daily,
diffuse, and/or aggravated by cough or straining. Although
this might be considered as a worse reliability and as a
risk of under-rating headache as a symptom in IIH (21), it
should be underlined that in pediatric population headache
characteristics are usually less defined than in adults. Moreover,
in younger children obtaining a precise description of headache
characteristics could be very difficult. In the ICHD-3, it is
only requested that headache must be “new” or show a
“significant worsening.” This latter expression, according to
ICHD-3 specifications, implies at least a double increase in
frequency and/or severity of headache. An objective evaluation
of a significant worsening was present in all the 3 patients
presenting a previous history of migraine, however it could
be difficult to be ascertained in younger patients. The ICHD-
3 criterion C states that the new or worsened headache
leads to the discovery of IIH, thus helping in evaluating
the fulfillment of this criterion. Summarizing, the significant
change in criterion A with the abolition of precise qualitative
characteristics defining headache could help to include a
higher rate of pediatric patients presenting with signs and
symptoms suggestive of IIH. Another important difference
between ICHD versions 2 and 3 is represented by the increase
of ICP cut-off in criterion B, keeping a difference between
patients with and without obesity. However, in our sample,
although limited, this modification did not determine any
difference.
A main feature of the ICHD-2 diagnostic criteria was
relief from headache after CSF withdrawal, but this was
removed in the recently published ICHD-3 criteria. In our
series, all patients had an improvement in symptoms after
lumbar puncture and CSF withdrawal, but this can be seen
also in patients with other types of headache (presenting
a sensitivity and specificity of 72 and 77%, respectively).
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This criterion has been replaced by the criterion according
to which headache should be “no better accounted for by
another ICHD-3 diagnosis.” This appeared to be a necessary
specification since headache secondary to IIH can be really
overlapping to chronic migraine or chronic tension-type
headache. Indeed, these disorders often coexist with IIH, and
in all patients still complaining of headaches after treatment,
migraine should be considered in order to use appropriate
treatment and prevent unnecessary overtreatment for suspected
IIH relapses (22).
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